VP, Clinical Development at Karuna Therapeutics
Inder Kaul, M.D., MPH is a strategic drug development executive with strong leadership and management skills. Dr. Kaul is an experienced global drug development leader with track record of success in regulatory project achievement worldwide, portfolio governance, translational science and commercialization support including medical affairs, life-cycle management, in-licensing and out-licensing evaluations. He has been a member of executive leadership teams inclusive of public companies, supported many business development/corporate transactions and interacted with board of directors, analysts and investors. Dr. Kaul is a versatile leader who has worked effectively within small, mid-size and large pharmaceutical/biotech companies and CROs. His expertise includes multiple therapeutic areas including neuroscience, orphan drug development and breakthrough designations. Dr. Kaul’s accomplishments include successful filing/support of 4 NDAs, 2 SNDAs and 1 BLA including 3 FDA Advisory Committee meetings; transition of 6 NCEs from Discovery to FIH clinical assessment including IND submissions; and successful filing of 2 PSPs and PIPs. Dr. Kaul’s employment history prior to joining Karuna Therapeutics includes executive management roles at Kaul Consulting LLC; Asahi Kasei Pharma America; Oscient Pharmaceuticals; Abt Associates Inc.; and AAI. Earlier in his career, Dr. Kaul held positions of increasing responsibility at Pfizer; Boehringer Ingelheim and Parexel International Corporation. Dr. Kaul received his M.D. in 1983, and MPH in 1988 from Harvard University.
VP, Clinical Development